Diagnostic system provider AutoGenomics sets terms for $60 million IPO
AutoGenomics, which provides a molecular diagnostics system for genetic testing in clinical laboratories, announced terms for its IPO on Wednesday. The Vista, CA-based company plans to raise $60 million by offering 6 million shares at a price range of $9 to $11. At the midpoint of the proposed range, AutoGenomics would command a fully diluted market value of $188 million. The company originally filed for an IPO in 2008 before withdrawing the registration in 2011. AutoGenomics, which was founded in 1999 and booked $17 million in sales for the 12 months ended 9/30/2012, plans to list on the NASDAQ under the symbol AGMX. Leerink Swann is the sole bookrunner on the deal.